PHILADELPHIA–(BUSINESS WIRE)–October 24, 2022–
Neuraptive Therapeutics, Inc., a biotechnology company dedicated to developing new therapeutic and medical products to address the unmet needs of physicians and patients affected by peripheral nerve injury, announced key organizational and financial updates.
Evan Tzanis has been named chief operating officer and executive vice president of research and development. Mr. Tzanis has served as Executive Vice President of Research and Development since joining Neuraptive in 2019, and will continue to report to Robert Radie, President and CEO. Mr. Tzanis has led the business from a preclinical-focused business to a clinical-stage business with two active INDs approved and two ongoing Phase 2 clinical studies with Fast Track designation. Additionally, Mr. Tzanis has played a critical role in guiding the company through significant organizational transition and fundraising.
Additionally, the company has hired Seth Schulman, MD as Medical Director reporting to Mr. Tzanis. Dr. Schulman had previously served as a consultant to the company. Dr. Schulman is a seasoned drug developer who held positions of increasing responsibility in clinical research from 2004 to 2019 at Wyeth and Pfizer Pharmaceuticals, and in 2014 Dr. Schulman became Head of Excellence and Innovation in Clinical Sciences within the Global Innovative Pharma business unit. Prior to joining Wyeth Pharmaceuticals, Dr. Schulman was a pediatric nephrologist at Children’s Hospital of Philadelphia (CHOP) and an associate professor of pediatrics and surgery at the University of Pennsylvania School of Medicine. Dr. Schulman has directly overseen hundreds of clinical trials and several product approvals in several therapeutic areas, including neurology.
“Mr. Tzanis’ appointment as COO recognizes his success in building high-performing teams and delivering strong results,” said Robert Radie, president and CEO of Neuraptive. “His expanded role includes overseeing and managing manufacturing, quality assurance, regulatory and other key internal company operations.”
“Dr. Schulman is a physician-scientist and clinical and operational leader with extensive experience overseeing and directing end-to-end clinical research and development studies, and I am delighted to have him on board. The Neuraptive team The appointment of Mr. Tzanis and the hiring of Dr. Schulman are aligned with the company’s continued progress toward the eventual filing of an NDA for its lead program, NTX1-001.
Finally, the company provided a financial update with the conversion of all previous debt to equity. More than $7.5 million in notes converted into preferred shares as the company met certain trigger criteria. The company currently has no outstanding debt.
Neuraptive Therapeutics, Inc. is a biotechnology company dedicated to developing new therapeutic and medical products to address the unmet needs of physicians and patients affected by peripheral nerve injuries. The company is headquartered in Philadelphia, Pennsylvania. For more information, visit www.neuraptive.com.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20221024005766/en/
CONTACT: [email protected]
KEYWORD: PENNSYLVANIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH OTHER HEALTH HEALTH PHARMACEUTICALS
SOURCE: Neuraptive Therapeutics, Inc.
Copyright BusinessWire 2022.
PUBLISHED: 10/24/2022 4:50 PM / DISK: 10/24/2022 4:51 PM